Sopkin v. Lopatto

District Court, District of Columbia·Decided September 19, 2024·No. Civil Action No. 2024-0743·Published

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

BARBARA SOPKIN, )

)

Plaintiff, )

)

v. ) Civil Action No. 24-0743 (TSC)

)

)

JOHN LOPATTO, )

)

Defendant. )

MEMORANDUM OPINION

This action, filed by Plaintiff Barbara Sopkin, see generally Compl., ECF No. 1-1 at 3– 35, proceeding pro se and in forma pauperis (“IFP”), was removed to this District from the Superior Court of the District of Columbia, by Defendant John Lopatto, see Def.’s Not. of Removal (“NOR”), ECF No. 1. Lopatto then filed a Motion to Dismiss (“MTD”), ECF No. 8, and supporting Memorandum (“MTD Mem.”), ECF No. 8-1, which Sopkin opposes, see Pl.’s Opposition to MTD (“Opp’n to MTD”), ECF No. 12, and moves to strike, see Pl.’s Mot. to Strike (“MTS”), ECF No. 14. Sopkin has also filed a Motion for Partial Summary Judgment (“MPSJ”), ECF No. 16, and a Motion to Remand to Superior Court (“MTR”), ECF No. 17, both of which are opposed by Lopatto, see Def.’s Opposition to MPSJ, ECF No. 19; Def.’s Opposition to MTR, ECF No. 20. For the reasons explained below, Sopkin’s Motion to Remand is granted. The remaining motions are all held in abeyance for resolution by the Superior Court.

BACKGROUND

This is not the first matter involving these parties; this case is the fifth action overall, and now the second lawsuit by Sopkin against Lopatto in this District. 1 Lopatto is a citizen of Virginia who maintains a law firm in the District of Columbia, and previously represented Sopkin, an Israeli citizen, as an assignee of Interlase, L.P., in three separate lawsuits. See id.; NOR ¶¶ 13–14; Compl. at caption, ¶¶ 1, 15, 67; Compl. Ex. 20, ECF No. 1-1, at 81–38 (Fee Agreement, dated Dec. 15, 2016) (“FA I”); Compl. Ex. 21, ECF No. 1-1, at 84–86 (Fee Agreement, Dated Aug. 27, 2021) (“FA II”). In Sopkin I, II, and III, Sopkin challenged the management of Interlase, a Georgia limited partnership that once held a corporate license agreement for specialized catheter patents in exchange for royalties. See Sopkin, 2023 WL 5833679, at *1–4. Sopkin purports to have long maintained an ownership interest in Interlase, originally conveyed to her by Lucre Investments, Ltd. See Sopkin, 2023 WL 5833679, at *1–4. In those three lawsuits, Sopkin alleged that Interlase’s former receiver, Richard Mendelson, failed to extend Interlase’s patents, negligently under-collected royalty payments, and permitted licensees to under-report the sales upon which those royalties were calculated, costing Interlase millions of dollars. See id.

None of those lawsuits were decided in Sopkin’s favor, and on October 27, 2022, she filed Sopkin IV against Lopatto in this District, raising claims for legal malpractice based on diversity jurisdiction, and alleging that, due to ineffective legal strategy, namely, failure to raise a

1 See Sopkin v. Lopatto, No. 22-cv-03300, 2023 WL 5833679, at *2–5 (D.D.C. Sept. 8, 2023) (“Sopkin IV”) (memorializing litigation history); see also Sopkin v. Mendelson, et al., No. 16-cv- 01146, 2017 WL 1536434 (E.D. Va. Apr. 27, 2017) (“Sopkin I”), aff’d, 746 Fed. Appx. 157 (4th Cir. 2018) (per curiam); Sopkin v. Mendelson, et al., No. 19-cv-58, 2019 WL 13251310 (E.D. Va. May 2, 2019) (“Sopkin II”), aff’d, 847 Fed. Appx. 197 (4th Cir. 2021) (per curiam); see Sopkin v. Mendelson, et al., No. CL-20004925-00 (Arlington Co. Cir. Ct. filed Dec. 1, 2020) (“Sopkin III”).

“surcharge theory” under Virginia law, Lopatto was responsible for her inability to recover Interlase’s $11,963,416 in lost patent-royalty payments. See id. at *5. She also claimed that Lopatto owed her for sanctions totaling $62,854.24, entered against her by the United States District Court for the Eastern District of Virginia in Sopkin I, because of allegedly frivolous claims he advanced on her behalf. See id.; see also Sopkin, 2022 WL 4002310 (E.D. Va. Sept. 1, 2022) (entering sanctions), aff’d, No. 22-1992, 2024 WL 1108825 (4th Cir. Mar. 14, 2024).

On September 8, 2023, this court entered a Memorandum Opinion and Order granting Lopatto’s Motion to Dismiss, dismissing the matter in full for want of subject matter jurisdiction. See id. at *11. In its Memorandum Opinion, the court detailed the relevant factual and procedural history, see id. at *1–4, and that Opinion is incorporated in full by reference herein, 2 see id. at *1–11.

In short, the court held that, despite holding herself out as the sole owner of Interlase, Sopkin could not recover the $11,963,416 in lost patent-royalty payments because, if they were owed, they belonged entirely to the entity. See id. at *6–9. First, the court found that Sopkin was prohibited from bringing any claims on behalf of Interlase. See id. at *7, *9. Three previous courts––the United States Court of Appeals for the Fourth Circuit, the Eastern District of Virginia, and the Arlington County Circuit Court––all previously ruled that Sopkin lacked standing to raise claims for Interlase. See id. at *7. More specifically, those courts found that

2 A court may “take judicial notice of related proceedings and records in cases before the same court.” Valore v. Islamic Republic of Iran, 700 F. Supp. 2d 52, 59 (D.D.C. 2010) (quoting Brewer v. Islamic Rep. of Iran, 664 F. Supp. 2d 43, 50–51 (D.D.C. 2009); Heiser v. Islamic Republic of Iran, 466 F. Supp. 2d 229, 267 (D.D.C. 2006); citing Fed. R. Evid. 201(b); Booth v. Fletcher, 101 F.2d 676, 679 n.2 (D.C. Cir. 1938) (“A court may take judicial notice of, and give effect to, its own records in another but interrelated proceeding[.]”) (other citation omitted)), cert. denied sub nom. Fletcher v. Booth, 307 U.S. 628 (1939).

Sopkin was so prohibited due to an injunction entered by the Arlington County Circuit Court on December 18, 1998, declaring Lucre a sham entity, and enjoining Lucre, its officers, managers, directors, and agents, from claiming to be Interlase’s partner, or taking any actions on its behalf. See id. at *1, *3. There was also no evidence to suggest that later conveyances (including those executed by the inventor and founding partner, Dr. Fox) afforded Sopkin any legal or beneficial interest in Interlase, or that she was otherwise qualified to bring a derivative suit. See id. at *3. Because the issue of Sopkin’s standing had been repeatedly previously litigated, this court found that Sopkin was collaterally estopped from relitigating the issue. See id. at *7.

Second, and notwithstanding the hurdle of collateral estoppel, this court found that Sopkin could not sue on behalf of Interlase due to the “shareholder standing rule.” See id. The court noted that no shareholder, not even a sole shareholder, has standing to sue in an individual capacity on a claim that belongs to the entity, and that prohibition extends to sole owners of limited partnerships. See id. at *6–7. Because the $11,963,416 in damages claimed by Sopkin arose “directly from injuries sustained by Interlase—in fact, they were sustained entirely by the entity—they d[id] not fall within any exception of the shareholder standing rule and . . . . [could not] survive as pleaded, regardless of whether they [were] brought as a direct or derivative suit against Mendelson, or whether they [were] brought as a derivative or direct legal malpractice suit against Lopatto.” Id. at *7.

Third, the court found that Sopkin could neither join nor substitute Interlase as a plaintiff.

See id. at *8. Because Sopkin was proceeding pro se, she was ineligible to sue on behalf of Interlase, and Interlase itself, as an artificial entity, could neither proceed pro se, nor apply to proceed IFP. Id. at *9.

Finally, the court found that Sopkin appeared to have standing to bring her last remaining claim for the sanctions-related damages because they were entered against her individually. Id. at *9. But those damages fell $12,000 short of the $75,000 threshold required to establish diversity jurisdiction. Id. For all these reasons, 3 Sopkin IV was dismissed pursuant to Federal Rule 12(b)(1). Id. at *11.

Free access — add to your briefcase to read the full text and ask questions with AI

Sopkin v. Lopatto, (D.D.C. 2024).

Sopkin v. Lopatto (Sopkin v. Lopatto) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Hertz Corp. v. Friend
559 U.S. 77 (Supreme Court, 2010)
Wilson v. Republic Iron & Steel Co.
257 U.S. 92 (Supreme Court, 1921)
Aetna Life Insurance v. Haworth
300 U.S. 227 (Supreme Court, 1937)
Shamrock Oil & Gas Corp. v. Sheets
313 U.S. 100 (Supreme Court, 1941)
Thomson v. Gaskill
315 U.S. 442 (Supreme Court, 1942)
Land v. Dollar
330 U.S. 731 (Supreme Court, 1947)
Cohen v. Beneficial Industrial Loan Corp.
337 U.S. 541 (Supreme Court, 1949)
Golden v. Zwickler
394 U.S. 103 (Supreme Court, 1969)
Pennsylvania v. New Jersey
426 U.S. 660 (Supreme Court, 1976)
Kremer v. Chemical Construction Corp.
456 U.S. 461 (Supreme Court, 1982)
Caterpillar Inc. v. Williams
482 U.S. 386 (Supreme Court, 1987)
Carden v. Arkoma Associates
494 U.S. 185 (Supreme Court, 1990)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
Taylor v. Sturgell
553 U.S. 880 (Supreme Court, 2008)
Monsanto Co. v. Geertson Seed Farms
561 U.S. 139 (Supreme Court, 2010)
Thomas, Oscar v. Principi, Anthony
394 F.3d 970 (D.C. Circuit, 2005)
American Nat. Ins. Co. v. FDIC
642 F.3d 1137 (D.C. Circuit, 2011)